Exelixis
EXEL
#1323
Rank
ยฃ12.64 B
Marketcap
ยฃ51.84
Share price
1.25%
Change (1 day)
64.65%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): ยฃ0.22

According to Exelixis's latest financial reports the company's current EPS (TTM) is ยฃ2.58. In 2022 the company made an earnings per share (EPS) of ยฃ0.42 a decrease over its 2021 EPS that were of ยฃ0.55.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)ยฃ0.22-47.69%
2022ยฃ0.42-22.97%
2021ยฃ0.55100%
2020ยฃ0.28-65.09%
2019ยฃ0.79-53.91%
2018ยฃ1.71333.96%
2017ยฃ0.39-260.61%
2016-ยฃ0.25-58.75%
2015-ยฃ0.60-42.45%
2014-ยฃ1.045.3%
2013-ยฃ0.9843.48%
2012-ยฃ0.69-264.29%
2011ยฃ0.42-165.88%
2010-ยฃ0.63-32.54%
2009-ยฃ0.94-17.65%
2008-ยฃ1.1475.86%
2007-ยฃ0.65-25.64%
2006-ยฃ0.878.33%
2005-ยฃ0.80-42.86%
2004-ยฃ1.4130.34%
2003-ยฃ1.08-5.23%
2002-ยฃ1.14-0.65%
2001-ยฃ1.15-51.88%
2000-ยฃ2.38

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
ยฃ4.98 93.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ0.57-78.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
ยฃ12.09 368.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
ยฃ1.42-45.00%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
ยฃ0.74-71.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ3.37 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
ยฃ2.14-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-ยฃ10.60-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-ยฃ0.63-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA